GLP-1 Peptide Atlas, by Delfa

CompletedPhase 2Results posted

A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities

A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities

Lead sponsor

Eli Lilly and Company

Asset

Orforglipron

Oral · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

272

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥30

Primary endpoint

•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05051579

Org study ID18210

Secondary ID2021-002805-88

Secondary IDJ2A-MC-GZGIEli Lilly and Company

Timeline

Milestones

Study first posted2021-09-21actual

Study start2021-09-29actual

Primary completion2022-08-25actual

Study completion2022-11-22actual

Last update posted2023-09-13actual

Results first posted2023-09-13actual

Assets

Investigational agents

Orforglipron

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Have a body mass index (BMI) of ≥30-kilogram square meter (kg/m²)

•Have a BMI ≥27 kg/m² and <30 kg/m² with at least 1 of the following weight-related comorbidities eg; [Have hypertension, or dyslipidemia, cardiovascular disease]

•Have had a stable body weight for the 3 months prior to randomization (not more than 5% body weight gain and/or loss)

Exclusion criteria

•Have any prior diagnosis of diabetes

•Have a prior or planned surgical treatment for obesity

•Have obesity induced by other endocrinological disorders or diagnosed monogenetic or syndromic forms of obesity

•Have renal impairment measured as estimated glomerular filtration rate (eGFR) <30 milliliter (mL)/minute (min)/1.73 m²

•Have a history of acute chronic pancreatitis

•Have a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 years Note: Participants with MDD or generalized anxiety disorder whose disease state is considered stable for the past 2 years and expected to remain stable throughout the course of the study, may be considered for inclusion if they are not on excluded medications.

Within 3 months prior to screening:

•Have poorly controlled hypertension

•Have history of acute myocardial infarction

•Have history of cerebrovascular accident (stroke)

•Had hospitalization due to congestive heart failure (CHF)

•Have cancer

•Have human immunodeficiency virus (HIV) and/or positive HIV antibodies historically or at screening

•Have hepatitis B and/or positive hepatitis B surface antigen

Endpoints (24)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

24 endpoints

Primary/registry result

Percent Change From Baseline in Body Weight in LY3502970 and Placebo

Time frame:Baseline, Week 26

Body weight, % change

percent change from baseline, improvement

Posted result

Group	Value (least_squares_mean), Percent change	95% CI
12 mg LY3502970	-8.6	—
24 mg LY3502970	-11.2	—
36 mg LY3502970	-12.3	—
45 mg LY3502970	-12.6	—
Placebo	-2.0	—

LS Mean difference (Final Values)-6.595% CI-8.9 – -4.2p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-9.295% CI-11.5 – -6.9p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-10.295% CI-12.4 – -8.0p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-10.695% CI-12.7 – -8.4p<0.001Mixed Models Analysis

Primary/protocol endpoint

Percent Change From Baseline in Body Weight in LY3502970 and Placebo

Time frame:Baseline, Week 26

Body weight, % change

percent change from baseline, improvement

Secondary/registry result

Percent Change From Baseline in Body Weight in LY3502970 and Placebo

Time frame:Baseline, Week 36

Body weight, % change

percent change from baseline, improvement

Posted result

Group	Value (least_squares_mean), Percent change	95% CI
12 mg LY3502970	-9.4	—
24 mg LY3502970	-12.5	—
36 mg LY3502970	-13.5	—
45 mg LY3502970	-14.7	—
Placebo	-2.3	—

LS Mean difference (Final Values)-7.195% CI-9.9 – -4.2p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-10.195% CI-12.9 – -7.3p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-11.195% CI-13.8 – -8.4p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-12.395% CI-15.0 – -9.6p<0.001Mixed Models Analysis

Secondary/registry result

Change From Baseline in Body Weight in LY3502970 and Placebo

Time frame:Baseline, Week 26

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kg	95% CI
12 mg LY3502970	-9.0	—
24 mg LY3502970	-12.3	—
36 mg LY3502970	-12.9	—
45 mg LY3502970	-13.3	—
Placebo	-2.1	—

LS Mean difference (Final Values)-6.995% CI-9.3 – -4.4p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-10.295% CI-12.5 – -7.8p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-10.895% CI-13.1 – -8.5p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-11.295% CI-13.5 – -8.9p<0.001Mixed Models Analysis

Secondary/registry result

Change From Baseline in Body Weight in LY3502970 and Placebo

Time frame:Baseline, Week 36

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kg	95% CI
12 mg LY3502970	-9.8	—
24 mg LY3502970	-13.6	—
36 mg LY3502970	-14.2	—
45 mg LY3502970	-15.4	—
Placebo	-2.4	—

LS Mean difference (Final Values)-7.495% CI-10.4 – -4.3p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-11.295% CI-14.2 – -8.3p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-11.895% CI-14.7 – -9.0p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-13.095% CI-15.8 – -10.2p<0.001Mixed Models Analysis

Secondary/registry result

Change From Baseline in Waist Circumference in LY3502970 and Placebo

Time frame:Baseline, Week 26

Waist circumference, change

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), centimeter (cm)	95% CI
12 mg LY3502970	-8.0	—
24 mg LY3502970	-8.8	—
36 mg LY3502970	-10.1	—
45 mg LY3502970	-12.2	—
Placebo	-3.6	—

LS Mean difference (Final Values)-4.495% CI-7.2 – -1.6p0.002Mixed Models Analysis

LS Mean difference (Final Values)-5.295% CI-8.0 – -2.4p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-6.595% CI-9.2 – -3.8p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-8.795% CI-11.3 – -6.0p<0.001Mixed Models Analysis

Secondary/registry result

Change From Baseline in Waist Circumference in LY3502970 and Placebo

Time frame:Baseline, Week 36

Waist circumference, change

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), cm	95% CI
12 mg LY3502970	-9.6	—
24 mg LY3502970	-11.2	—
36 mg LY3502970	-10.6	—
45 mg LY3502970	-13.6	—
Placebo	-4.0	—

LS Mean difference (Final Values)-5.695% CI-8.8 – -2.4p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-7.295% CI-10.3 – -4.0p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-6.695% CI-9.7 – -3.6p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-9.695% CI-12.7 – -6.6p<0.001Mixed Models Analysis

Secondary/registry result

Change From Baseline in BMI in LY3502970 and Placebo

Time frame:Baseline, Week 26

BMI, change

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kilograms per meter square (kg/m^2)	95% CI
12 mg LY3502970	-3.2	—
24 mg LY3502970	-4.2	—
36 mg LY3502970	-4.6	—
45 mg LY3502970	-4.7	—
Placebo	-0.8	—

LS Mean difference (Final Values)-2.495% CI-3.2 – -1.6p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-3.595% CI-4.3 – -2.6p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-3.895% CI-4.6 – 3.0p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-3.995% CI-4.7 – -3.1p<0.001Mixed Models Analysis

Secondary/registry result

Change From Baseline in BMI in LY3502970 and Placebo

Time frame:Baseline, Week 36

BMI, change

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kg/m^2	95% CI
12 mg LY3502970	-3.4	—
24 mg LY3502970	-4.7	—
36 mg LY3502970	-5.0	—
45 mg LY3502970	-5.5	—
Placebo	-0.9	—

LS Mean difference (Final Values)-2.595% CI-3.6 – -1.5p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-3.895% CI-4.8 – -2.8p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-4.295% CI-5.2 – -3.2p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-4.695% CI-5.6 – -3.6p<0.001Mixed Models Analysis

Secondary/registry result

Percentage of Participants With >=5% Body Weight Loss

Time frame:Week 26

≥5% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), percentage of participants	95% CI
12 mg LY3502970	74.39	—
24 mg LY3502970	88.84	—
36 mg LY3502970	89.46	—
45 mg LY3502970	87.26	—
Placebo	22.88	—

Odds Ratio (OR)9.9695% CI3.61 – 27.44p<0.001Regression, Logistic

Odds Ratio (OR)27.9795% CI8.15 – 96.01p<0.001Regression, Logistic

Odds Ratio (OR)27.3695% CI8.71 – 85.91p<0.001Regression, Logistic

Odds Ratio (OR)23.5995% CI7.65 – 72.77p<0.001Regression, Logistic

Secondary/registry result

Percentage of Participants With >=10% Body Weight Loss

Time frame:Week 26

≥10% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), percentage of participants	95% CI
12 mg LY3502970	39.39	—
24 mg LY3502970	56.61	—
36 mg LY3502970	71.30	—
45 mg LY3502970	69.86	—
Placebo	2.25	—

Odds Ratio (OR)19.9395% CI3.47 – 114.40p<0.001Regression, Logistic

Odds Ratio (OR)39.5295% CI6.95 – 224.83p<0.001Regression, Logistic

Odds Ratio (OR)74.9795% CI13.16 – 427.18p<0.001Regression, Logistic

Odds Ratio (OR)72.2395% CI12.62 – 413.21p<0.001Regression, Logistic

Secondary/registry result

Percentage of Participants With >=5% Body Weight Loss

Time frame:Week 36

≥5% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), percentage of participants	95% CI
12 mg LY3502970	72.00	—
24 mg LY3502970	89.47	—
36 mg LY3502970	92.05	—
45 mg LY3502970	90.44	—
Placebo	24.02	—

Odds Ratio (OR)7.7995% CI2.90 – 20.92p<0.001Regression, Logistic

Odds Ratio (OR)25.0795% CI7.49 – 83.91p<0.001Regression, Logistic

Odds Ratio (OR)34.7695% CI8.17 – 147.86p<0.001Regression, Logistic

Odds Ratio (OR)28.0195% CI8.15 – 96.29p<0.001Regression, Logistic

Secondary/registry result

Percentage of Participants With >=10% Body Weight Loss

Time frame:Week 36

≥10% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), percentage of participants	95% CI
12 mg LY3502970	46.50	—
24 mg LY3502970	61.88	—
36 mg LY3502970	74.75	—
45 mg LY3502970	69.07	—
Placebo	8.85	—

Odds Ratio (OR)8.2795% CI2.59 – 26.45p<0.001Regression, Logistic

Odds Ratio (OR)15.6495% CI4.83 – 50.68p<0.001Regression, Logistic

Odds Ratio (OR)27.2495% CI8.39 – 88.38p<0.001Regression, Logistic

Odds Ratio (OR)20.8895% CI6.59 – 66.17p<0.001Regression, Logistic

Secondary/protocol endpoint

Percent Change From Baseline in Body Weight in LY3502970 and Placebo

Time frame:Baseline, Week 36

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Body Weight in LY3502970 and Placebo

Time frame:Baseline, Week 26

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Body Weight in LY3502970 and Placebo

Time frame:Baseline, Week 36

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Waist Circumference in LY3502970 and Placebo

Time frame:Baseline, Week 26

Waist circumference, change

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Waist Circumference in LY3502970 and Placebo

Time frame:Baseline, Week 36

Waist circumference, change

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in BMI in LY3502970 and Placebo

Time frame:Baseline, Week 26

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in BMI in LY3502970 and Placebo

Time frame:Baseline, Week 36

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Percentage of Participants With >=5% Body Weight Loss

Time frame:Week 26

≥5% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants With >=10% Body Weight Loss

Time frame:Week 26

≥10% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants With >=5% Body Weight Loss

Time frame:Week 36

≥5% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants With >=10% Body Weight Loss

Time frame:Week 36

≥10% weight-loss responders

threshold achievement, improvement

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes.
Cardiovascular diabetology2025 Jun 6PMID40481478doi:10.1186/s12933-025-02781-xvia clinicaltrials gov reference derived + pubmed nct search
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
The New England journal of medicine2023 Sep 7PMID37351564doi:10.1056/NEJMoa2302392via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.